Pressure Point

Brown scientists have discovered a key driver of preeclampsia, which causes high blood pressure during pregnancy. By Dana Laverty

Researchers at Brown University have identified a protein in cerebrospinal fluid that’s a driver in preeclampsia, a dangerous pregnancy condition that affects between 5 to 8 percent of pregnancies and is a leading cause of maternal and fetal death.

Research led by Surendra Sharma and Sukanta Jash at Brown University and Kun Ping Lu and Xia Zhen Zhou at Western University in Canada found the protein, cis P-tau, in the blood and placentas of people with preeclampsia. They also found that depleting cis P-tau prevented mice from developing the condition. 

“Our study identifies cis P-tau as a culprit and biomarker for preeclampsia,” says Sharma, who until recently was a Brown professor of pathology and laboratory medicine and professor of pediatrics. “It can be used for early diagnosis of the complication and is a crucial therapeutic target.” (Sharma is now a professor of obstetrics and gynecology at the University of Texas Medical Branch in Galveston.)

Preeclampsia is a complication that results in high blood pressure during pregnancy. Untreated, it can lead to serious complications for both the mother and baby, and often leads to preterm labor and birth. 

The protein cis P-tau has mainly been associated with Alzheimer’s disease, traumatic brain injuries and stroke. Lu and Zhou discovered the association in 2015.

Screening tests for the cis P-tau biomarker, combined with therapies involving the cis P-tau antibody, could change the outlook for pregnant people with preeclampsia, Jash says. The root cause of preeclampsia has so far remained unknown, Sharma says, and without a known cause there has been no cure.

The team at Brown is currently working on developing a lab test that can detect preeclampsia.

__________

Bridging the Gap

Researchers from Brown University and Lifespan are partnering on a device that could restore function for individuals with a spinal cord injury. By Lauren Clem

A clinician works with a participant in the trial. Photo courtesy of Lifespan

In an unassuming building on Allens Avenue in Providence, research is underway that could change the future of spinal cord injury treatment.

The Intelligent Spine Interface, led by researchers from Brown University and surgeons from Rhode Island Hospital, aims to restore limb motor function, sensation, autonomic function and bladder control for individuals paralyzed following a spinal cord injury. According to principal investigator David Borton, an associate professor of engineering and brain science at Brown University and biomedical engineer with the Department of Veterans Affairs, no technology currently exists to bridge the gap created by such an injury.

“There’s no tool or a magic fix that we have for someone who has a complete spinal cord injury,” he says. “There’s nothing available to help them regain functions that they have lost.”

Working with Dr. Jared Fridley, director of the Spinal Outcomes Laboratory at Lifespan and an associate professor of neurosurgery at Brown, the team is creating a device that would carry signals across the injury site and restore the connection between brain and limbs. The device uses artificial intelligence to interpret signals from the spinal cord and adapt to the needs of the wearer over time.

“These devices enable the person’s spinal cord and nervous system to modulate over time to hopefully recover function,” Fridley says. “For most people, we’re talking about weeks to months of rehabilitation, plus the device, to see if there’s recovery of function.”

David Borton and Dr. Jared Fridley, right, present their research to Yunyan “Jennifer” Wang and Jean-Paul Chretien of the Defense Advanced Research Projects Agency in Washington, D.C. Photo courtesy of DARPA.

The study, funded by the Defense Advanced Research Projects Agency and the Department of Veterans Affairs at the Providence VA Medical Center, has the potential to restore movement to those with spinal cord injuries, including veterans paralyzed in combat situations. A clinical trial is underway at Lifespan’s Center for Innovative Neurotechnology for Neural Repair, where the researchers have enlisted two individuals to participate in phase one of the trial.

“This is a first in human clinical study for this type of technology,” Borton says. “No one’s ever done this before.”

__________

Vasectomy Victor

There may be a faster and easier way to perform a vasectomy. By Jamie Coelho

Imagine if men could get a vasectomy in five seconds. There may be a new, minimally invasive way to conduct the procedure in our near future. On the heels of its five-year anniversary, Providence-based Signati Medical earned FDA approval for clinical trials for a study of a minimally invasive surgical device to perform a sealed vasectomy procedure (SVP). 

Photo courtesy of Signati Medical.

Advertisement

Signati Medical is a medical device company working to advance men’s health. Signati CEO William Prentice says the study kicked off this April with its first patient at Louisiana State University Medical Center, and they plan to have an additional seven people undergo the procedure by the end of the month. The device obstructs the vas deferens by sending a shock through the skin that seals the tubes, rather than a surgeon cutting and fusing. 

Prentice wants to undergo SVP on live TV to gain support, but he must wait until the procedure is fully approved. “I agreed to do it,” he says. “We should be doing this for women. There’s no reason women need to go in for tubal ligations and have major surgery, take birth control pills or get IUDs. Men think because they have a vasectomy, they are not going to get an erection. It really shouldn’t be that way.” 

Prentice says this is the first innovation in vasectomy in more than twenty years. 

“About twenty years ago, one thing changed and that was that they went from scalpel to no scalpel,” he says. “This procedure takes about five seconds. Bipolar sealing in the body is the best sealing you can get.” signatimed.com